Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole for mild Alzheimer's disease
IRCT20100126003181N4Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Riluzole with Placebo (2 arms). Primary endpoints: Cognitive function, Memory performance and 1 more. Started Apr 2018; status: completed.
02
Drugs
riluzole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on IRCT20100126003181N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100126003181N4.